{"id":"influenza-split-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site soreness"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Fever"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Split vaccines contain disrupted influenza virions that expose internal and surface antigens without intact infectious particles. This formulation triggers both humoral (antibody) and cell-mediated immune responses, providing protection against seasonal influenza strains included in the vaccine composition. The split design reduces reactogenicity compared to whole-virion vaccines while maintaining immunogenicity.","oneSentence":"A split influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against inactivated influenza virus antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:04.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT04381689","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-23","conditions":"Healthy","enrollment":245},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT07349017","phase":"PHASE1","title":"A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-02-07","conditions":"Influenza","enrollment":160},{"nctId":"NCT07327398","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2026-01-07","conditions":"Influenza","enrollment":1200},{"nctId":"NCT07302256","phase":"PHASE1","title":"A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above","status":"RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-12-16","conditions":"Influenza","enrollment":120},{"nctId":"NCT05645900","phase":"PHASE3","title":"A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-02-06","conditions":"Influenza","enrollment":2772},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT06641180","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-04","conditions":"Influenza","enrollment":1180},{"nctId":"NCT00800605","phase":"PHASE3","title":"Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-12","conditions":"Influenza","enrollment":7250},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT06095947","phase":"","title":"Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-09-15","conditions":"GCP","enrollment":652},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06695130","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-18","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT06738082","phase":"","title":"Influenza Vaccine Elicited Immune Response in Immunocompromised Patients","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-10-15","conditions":"Influenza Vaccine, Immunocompromised Patients","enrollment":147},{"nctId":"NCT06059456","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-02","conditions":"Influenza Immunization (Healthy Volunteers)","enrollment":2078},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT06342349","phase":"PHASE1","title":"A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-03-30","conditions":"Influenza","enrollment":300},{"nctId":"NCT06800950","phase":"PHASE3","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-02-08","conditions":"Influenza, Human, Influenza, Human Prevention, Influenza a","enrollment":4400},{"nctId":"NCT06622590","phase":"PHASE1","title":"Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-10-13","conditions":"Influenza, Human, Influenza a, Influenza Type B","enrollment":180},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":"H7N9 Influenza","enrollment":560},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT03160118","phase":"PHASE4","title":"Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-03-27","conditions":"Prevention of Influenza","enrollment":20},{"nctId":"NCT01538940","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-11-01","conditions":"Influenza","enrollment":415},{"nctId":"NCT05431725","phase":"PHASE3","title":"Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-07-18","conditions":"Seasonal Influenza","enrollment":2202},{"nctId":"NCT06334510","phase":"","title":"Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-11-17","conditions":"GCP","enrollment":4900},{"nctId":"NCT05568979","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-06","conditions":"Influenza (Healthy Volunteers)","enrollment":1001},{"nctId":"NCT06304038","phase":"","title":"Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2017-10-16","conditions":"Influenza Vaccine, Cost-Benefit Analysis","enrollment":5483},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT00566345","phase":"PHASE3","title":"Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-11","conditions":"Influenza","enrollment":3670},{"nctId":"NCT01551823","phase":"PHASE3","title":"The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Influenza","enrollment":1200},{"nctId":"NCT01551810","phase":"PHASE3","title":"The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-03","conditions":"Influenza","enrollment":1200},{"nctId":"NCT05512494","phase":"PHASE4","title":"Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-11-27","conditions":"Seasonal Influenza","enrollment":1260},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT05739474","phase":"PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children","status":"UNKNOWN","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2022-01-19","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":948},{"nctId":"NCT05138705","phase":"PHASE4","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2021-12-14","conditions":"Influenza, Human","enrollment":380},{"nctId":"NCT04695717","phase":"PHASE3","title":"This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2020-09-05","conditions":"Influenza","enrollment":864},{"nctId":"NCT04176133","phase":"PHASE2","title":"Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination","status":"COMPLETED","sponsor":"Robert J. Pignolo","startDate":"2019-10-30","conditions":"Healthy","enrollment":61},{"nctId":"NCT05107375","phase":"PHASE3","title":"Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-09-03","conditions":"Coronavirus Disease 2019","enrollment":299},{"nctId":"NCT05869201","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-10-06","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":450},{"nctId":"NCT05832333","phase":"","title":"Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-05","conditions":"Influenza","enrollment":682},{"nctId":"NCT05078060","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-10-12","conditions":"Influenza (Healthy Volunteers)","enrollment":1804},{"nctId":"NCT03930017","phase":"","title":"Pregnancy, Arsenic and Immune Response","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-10-14","conditions":"Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired","enrollment":784},{"nctId":"NCT03430089","phase":"PHASE1","title":"Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-02-22","conditions":"Influenza, Flu","enrollment":101},{"nctId":"NCT05308212","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2021-03-04","conditions":"Influenza","enrollment":633},{"nctId":"NCT05212623","phase":"PHASE1","title":"A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-10-26","conditions":"Influenza","enrollment":120},{"nctId":"NCT04091880","phase":"PHASE4","title":"Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2019-09-26","conditions":"Enterovirus Infections, Influenza","enrollment":1134},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT05470582","phase":"PHASE3","title":"Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2021-02-16","conditions":"Influenza, Human, Vaccination; Infection, Vaccines","enrollment":1066},{"nctId":"NCT05457894","phase":"PHASE3","title":"Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-01-23","conditions":"Influenza, Human, Vaccination; Infection, Vaccines","enrollment":207},{"nctId":"NCT05406180","phase":"","title":"Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-10-10","conditions":"Influenza","enrollment":675},{"nctId":"NCT05389137","phase":"PHASE4","title":"To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years","status":"UNKNOWN","sponsor":"Wuhan Institute of Biological Products Co., Ltd","startDate":"2022-03-02","conditions":"Influenza","enrollment":360},{"nctId":"NCT03391193","phase":"PHASE3","title":"Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-12-19","conditions":"Influenza","enrollment":301},{"nctId":"NCT03765437","phase":"PHASE3","title":"Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-01-15","conditions":"Influenza","enrollment":230},{"nctId":"NCT05317767","phase":"PHASE3","title":"The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-02-10","conditions":"Influenza","enrollment":600},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05312294","phase":"PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-12-07","conditions":"Influenza, Flu, Human","enrollment":654},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT05297994","phase":"PHASE2","title":"Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2016-10-24","conditions":"Influenza","enrollment":400},{"nctId":"NCT02550197","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":300},{"nctId":"NCT05126979","phase":"PHASE1","title":"The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2016-03-09","conditions":"Influenza","enrollment":45},{"nctId":"NCT05089123","phase":"PHASE3","title":"The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-03-03","conditions":"Influenza","enrollment":320},{"nctId":"NCT05152017","phase":"PHASE1","title":"The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2019-11-16","conditions":"Influenza","enrollment":75},{"nctId":"NCT03589807","phase":"PHASE2","title":"2013/2017 H7N9 Prime-Boost Interval","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-21","conditions":"Avian Influenza, Influenza Immunisation","enrollment":180},{"nctId":"NCT03738241","phase":"PHASE2","title":"2017 A/H7N9 IIV Revaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-18","conditions":"Avian Influenza, Influenza Immunisation","enrollment":304},{"nctId":"NCT00956111","phase":"PHASE4","title":"A Clinical Trial With Influenza A/H1N1 Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2009-07","conditions":"Influenza","enrollment":1614},{"nctId":"NCT03300050","phase":"PHASE1","title":"Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2017-10-10","conditions":"Influenza, Vaccine","enrollment":65},{"nctId":"NCT00929331","phase":"PHASE3","title":"Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07-11","conditions":"Influenza, Human","enrollment":110},{"nctId":"NCT01157702","phase":"PHASE3","title":"Yearly Strain Variation Study, 2010/2011","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2010-07","conditions":"Influenza, Seasonal Influenza","enrollment":110},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT02263131","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2013-10","conditions":"Healthy","enrollment":416},{"nctId":"NCT03445468","phase":"PHASE3","title":"Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2017-09-20","conditions":"Influenza, Human","enrollment":379},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT00449670","phase":"PHASE3","title":"Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-24","conditions":"Influenza, Influenza Vaccines","enrollment":1206},{"nctId":"NCT02894840","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-11","conditions":"Influenza","enrollment":340},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT03095599","phase":"PHASE2, PHASE3","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2017-03-20","conditions":"Influenza, Human","enrollment":889},{"nctId":"NCT00586469","phase":"PHASE4","title":"A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-14","conditions":"Influenza Vaccines","enrollment":1000},{"nctId":"NCT00718120","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-18","conditions":"Influenza Vaccines","enrollment":110},{"nctId":"NCT00385255","phase":"PHASE3","title":"Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-23","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":1726},{"nctId":"NCT02935192","phase":"PHASE3","title":"Phase 3 Trial of Serbian Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2016-11-28","conditions":"Influenza","enrollment":480},{"nctId":"NCT00138398","phase":"NA","title":"T-cell Response-Flu Risk in Older Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10-25","conditions":"Influenza","enrollment":850},{"nctId":"NCT02598089","phase":"PHASE1","title":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT02585700","phase":"PHASE1","title":"A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine","status":"COMPLETED","sponsor":"Institute of Virology, Vaccines and Sera, Torlak","startDate":"2015-11","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT00750360","phase":"PHASE4","title":"Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-03","conditions":"Influenza","enrollment":883},{"nctId":"NCT00502593","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":"Influenza","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Shenzhen Aventis Pasteur","Hualan Biologicals"],"phase":"phase_3","status":"active","brandName":"Influenza split vaccine","genericName":"Influenza split vaccine","companyName":"Hualan Biological Engineering, Inc.","companyId":"hualan-biological-engineering-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"A split influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against inactivated influenza virus antigens. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}